Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2013 ASCO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Richard D. Carvajal on the Investigation of Selumetinib
Dr. Swain Discusses Studies From the 2013 ASCO Meeting
Dr. Sartor on the Mechanism of Action of Radium-223
Oncology Conference Articles
Novel Hsp Inhibitor May Offer NSCLC Salvage Option
Salvage therapy combining the novel heat shock protein 90 inhibitor ganetespib with docetaxel significantly improved overall survival in some patients with nonâ€“small cell lung cancer.
Axillary Radiotherapy Equal to Surgery in Early Breast Cancer
Women with early sentinel lymph node-positive breast cancer achieve as much of a disease-free and survival benefit from axillary radiotherapy as they do from axillary lymph node dissection with significantly less risk of lymphedema.
Optimal Paclitaxel Schedule Identified for Early-Stage Breast Cancer
Low-dose weekly paclitaxel is as effective and has fewer side effects than the standard biweekly schedule for patients with early-stage breast cancer.
Vinegar Proves to Be Effective, Widely Implementable Cervical Cancer Screening Tool
A simple visual screening test using vinegar has the potential to dramatically reduce the number of deaths from cervical cancer in the developing world, according to findings from a large study in India, where use of the screening tool yielded a 31% reduction in cervical cancer mortality.
Drug Shortages Adversely Affect Treatment Decisions
Shortages of cancer drugs caused many oncologists and hematologists to choose suboptimal treatment plans for their patients last year, and government efforts have done little to boost the availability of the hard-to-find medications.
More Evidence for 10-Years of Tamoxifen in ER+ Breast Cancer
A British study has confirmed that 10 years of adjuvant tamoxifen substantially reduces late breast cancer recurrence and mortality among women with estrogen receptor-positive disease.
Bevacizumab Improves Survival in Advanced Cervical Cancer
Bevacizumab combined with either of two chemotherapy backbones improved overall survival by 3.7 months versus chemotherapy alone in patients with advanced cervical cancer.
Sorafenib Doubles PFS in Rare Thyroid Cancer
Interim findings from a randomized, global, phase III study indicate that the multi-targeted drug sorafenib nearly doubled PFS for patients with differentiated thyroid cancer resistant to radioactive iodine therapy.
First-Line Bevacizumab Does Not Improve Survival in Glioblastoma
Adding bevacizumab to a standard treatment regimen for glioblastoma consisting of chemoradiation with temozolomide in newly diagnosed patients does not improve OS and did not significantly improve PFS.
GM-CSF Boosts Ipilimumab Efficacy in Metastatic Melanoma
Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.
Partners of HPV-Positive Oropharyngeal Cancer Patients Not at Increased Risk of HPV Infection or Oral Cancer
Patients with human papilloma virusâ€“positive oropharyngeal cancer and their spouses may find some reassurance in a study that found that partners are no more likely to be infected by HPV than the general population.
Maintenance Therapy With Pazopanib Delays Relapse of Advanced Ovarian Cancer
An oral targeted drug already approved by the FDA for the treatment of kidney cancer and soft tissue sarcoma has been found to extend disease-free survival in women with advanced ovarian cancer.
Cetuximab OS Results Top Bevacizumab in mCRC
Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.
Nivolumab Delivers Enduring Benefits in Advanced Melanoma
Nivolumab has demonstrated an overall objective response rate of 31% with a median duration of two years in patients with advanced melanoma.
ASCO Highlights Put Variety in Spotlight
New data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year's Annual Meeting of the ASCO, according to industry analysts.
ASCO Opens 49th Annual Meeting Urging More Federal Funding for Research
The American Society of Clinical Oncology kicked off its 49th Annual Meeting with leaders urging all stakeholders in cancer care to vigorously oppose cuts to vital US biomedical research funding.
Four Head and Neck Cancer Highlights From ASCO 2013
This article summarizes 4 abstracts that will be discussed at the 49th Annual ASCO Meeting, focused on the treatment of patients with head and neck cancer.
Combining Ipilimumab and Nivolumab Shows Promise in Advanced Melanoma
Combining the checkpoint antibodies ipilimumab and nivolumab led to deep tumor regression in approximately one-third of patients with advanced melanoma.
High Levels of Cardiovascular Fitness Reduces the Risk of Developing and Dying From Cancer
Men with a high level of cardiovascular fitness at middle age had a reduced risk of developing and dying from lung and colorectal cancer later in life.
New PI3K-delta Inhibitor Prolongs Survival in Chronic Lymphocytic Leukemia
The novel selective PI3K-delta inhibitor idelalisib produced rapid and prolonged tumor shrinkage in patients with relapsed or refractory chronic lymphocytic leukemia who received the drug as a monotherapy.
Adjuvant Surveillance Effective in Early-Stage Seminoma
Active surveillance following radical orchiectomy is an effective treatment strategy for men with stage I seminoma.
Follow-Up Scans Do Little to Detect Relapse of Diffuse Large B-Cell Lymphoma
Routine follow-up imaging is of limited value in determining whether patients with diffuse large B-cell lymphoma have experienced a relapse of their disease.
In Treating Locally Advanced NSCLC, More Radiotherapy Is Not Better
Radiotherapy at a higher-than-standard dose is harmful to patients with locally advanced non-small cell lung cancer who are also getting concurrent and consolidation chemotherapy.
Early Results Robust for New PD-L1 Immunotherapy Agent
An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.
FDA Approvals in Non-Hodgkin Lymphoma, Breast Cancer, GVHD, and Mesothelioma
Imetelstat Provides Durable Transfusion Independence in Lower-Risk Relapsed/Refractory MDS
New Macrophage Immune Checkpoint Strategy Shows Promise in AML and MDS
Elotuzumab Triplet Continues to Show Survival Benefit in Relapsed/Refractory Myeloma
Frontline Venetoclax/Obinutuzumab Combo Emerges as Treatment Option for CLL With CKT
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.